top of page

Daphne Zohar on becoming the CEO of Seaport Therapeutics and today's $100M series A

She describes working with Steven Paul again, the Glyph technology that is the backbone of Seaport's platform, and initial programs in the neuropsychiatry space.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page